Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab vs placebo in pediatric moderate-to-severe atopic dermatitis
2022-501476-25-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab with Placebo (2 arms). Primary endpoints: IGA 0/1 with ≥2-point reduction from baseline and EASI-75 response. Started Jul 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-501476-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501476-25-00.